Explore Our Active Clinical Trials*


Seagen®

Tap on a trial to learn more


Investigating Established Agents in New Treatment Areas or Settings




Late-Stage ADCs




Early-Stage ADCs





Other Targeted Modalities











*The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

EV-104 | Intravesical EV

AYA: adolescents and young adults; BCG: bacillus Calmette-Guérin; CD: cluster of differentiation; EBC: early breast cancer; HER2: human epidermal growth factor receptor 2

Advanced solid tumors

SGNCEA5C-001 | 2L+

^aProgram being co-developed with Takeda Pharmaceutical Company, Ltd.; ^bProgram being co-developed with Astellas Pharma Global Development, Inc.; ^cStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD). Enrolling in a China-specific extension only; ^dStudy sponsored by MSD, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.; ^eStudy sponsored by MSD; Substudy 04B of KEYMAKER-U04 umbrella study; ^fStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and MSD; ^gTrial being conducted by the Alliance for Clinical Trials in Oncology; ^hTrial being co-developed with MSD; ^kTrial in collaboration with RemeGen Co., Ltd. and MSD